ValuEngine downgraded shares of Kamada Ltd. (NASDAQ:KMDA) from a hold rating to a sell rating in a research report released on Friday morning.

A number of other equities analysts have also recently issued reports on the company. Zacks Investment Research cut Kamada from a hold rating to a strong sell rating in a report on Thursday, May 18th. TheStreet cut Kamada from a c- rating to a d+ rating in a report on Tuesday, August 1st. Finally, Jefferies Group LLC restated a buy rating and issued a $9.00 target price on shares of Kamada in a report on Wednesday, May 17th. One analyst has rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus target price of $7.67.

Shares of Kamada (NASDAQ KMDA) traded up 1.11% during mid-day trading on Friday, hitting $4.55. The stock had a trading volume of 92,330 shares. Kamada has a 12-month low of $3.75 and a 12-month high of $8.61. The company has a 50 day moving average price of $4.74 and a 200 day moving average price of $6.40. The firm’s market cap is $170.17 million.

Kamada (NASDAQ:KMDA) last issued its earnings results on Tuesday, August 1st. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.12 by $0.01. The business had revenue of $32.55 million for the quarter, compared to analysts’ expectations of $33.30 million. Kamada had a negative return on equity of 2.94% and a negative net margin of 2.24%. The company’s quarterly revenue was up 70.7% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.04) EPS. Equities analysts forecast that Kamada will post $0.06 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Kamada Ltd. (KMDA) Downgraded by ValuEngine to “Sell”” was first posted by Daily Political and is the property of of Daily Political. If you are accessing this piece on another publication, it was copied illegally and republished in violation of international copyright laws. The correct version of this piece can be viewed at

Hedge funds have recently modified their holdings of the company. Nexthera Capital LP acquired a new stake in shares of Kamada during the second quarter valued at approximately $1,805,000. Acadian Asset Management LLC purchased a new stake in Kamada during the first quarter worth about $575,000. Norges Bank purchased a new stake in Kamada during the fourth quarter worth about $377,000. Navellier & Associates Inc purchased a new stake in Kamada during the second quarter worth about $303,000. Finally, Renaissance Technologies LLC boosted its stake in Kamada by 16.7% in the first quarter. Renaissance Technologies LLC now owns 264,800 shares of the biotechnology company’s stock worth $1,801,000 after buying an additional 37,800 shares during the last quarter. 7.15% of the stock is owned by institutional investors and hedge funds.

Kamada Company Profile

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.

Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with's FREE daily email newsletter.